[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-respiratory-conditions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-respiratory-conditions":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100640756","pulmonary-rehabilitation-in-african-countries-100640756",false,"NCT07602673","Pulmonary Rehabilitation in African Countries","Respiratory Medicine and Pulmonary Rehabilitation Feasibility Study and Randomised Controlled Trial in Nigeria, South Africa and Cameroon","Inclusion Criteria:\n\n* Male and female adults (\\>= 18 years) with specified clinical diagnosis (typically by detailed clinical history \\[persistent symptoms for ≥6 months\\] plus spirometry and\u002For other available tests, e.g., chest X-ray\\]\n* Individuals with CRDs, specifically COPD, asthma or post-tuberculosis lung disorder\n* Patients with CRDs who have an indication for PR (specifically, these are patients with moderate to severe staged disease who present with reduced exercise\u002Ffunctional capacity, poor quality of life, high disease symptoms, particularly dyspnea) and are medically fit to undergo exercise training (which is to be determined by pre-exercise screening and field tests).\n* Patients with CRDs attending regular follow-up in the respiratory clinics of the selected centres.\n* Patients who are willing and able to provide written or oral (audio recorded) informed consent\n* All levels (primary, secondary, and tertiary) of healthcare professionals, including doctors, nurses, physiotherapists, respiratory therapists, medical assistants, healthcare administrators, pulmonologists, and other formal practitioners working in primary, secondary, and tertiary care settings, who provide services to patients who may potentially require PR.\n* Relevant stakeholders, including policymakers, religious leaders, sports leaders, the pharmaceutical industry, social workers, managers, and hospital\u002Fpractice owners.\n* Willing and able to provide written or oral (audio recorded) informed consent.\n\nExclusion Criteria:\n\n* Patients with other significant chronic co-morbidities such as heart failure, ischemic heart disease, DM, and confusion\u002Fdementia\n* Pregnant women\n* Co-morbidity that is a contraindication to PR (e.g., unstable angina, aortic aneurysm, recent myocardial infarction, acute infection, etc.)\n* Significant cognitive or physical impairment preventing participation in PR\n* Active pulmonary tuberculosis vi. Patient with current or recent disease exacerbations\n* Non-respiratory cause for symptoms (e.g., breathlessness due to heart failure, anaemia)\n* Unable to participate in exercise (e.g., due to severe arthritis or paralysis)\n* Undertaken PR within one year.\n* Unwilling to participate in the study.\n* Unable to give written or oral (audio recorded) informed consent\n* Healthcare professionals who are not involved in the care of patients who require PR, e.g., midwives\n* Having a conflict of interest that may influence the outcome\n* Unable and unwilling to give written or oral (audio recorded) informed consent","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"NA","Chronic Respiratory Diseases (CRDs) are common disabling conditions worldwide with high prevalence, morbidity and mortality. More than half of the CRD patients live in low- and middle-income countries (LMICs) where resources for identifying the condition, understanding the disease status of individual patients, and overall management are often poor. CRDs in high-income countries (HICs) are dominated by chronic obstructive pulmonary disease (COPD) and asthma, whereas in LMICs, post-tuberculosis (TB) lung disorders, bronchiectasis, and other (often unidentified) respiratory conditions contribute to a significant proportion of CRDs. Pulmonary rehabilitation (PR) is an essential component of evidence-based clinical management guidelines for CRDs, though most of the evidence on PR is disease-specific and generated from HICs. A recent systematic review by the RESPIRE group, with whom we collaborate, revealed that 12 out of 13 studies suggested that PR for patients with CRDs in LMICs was an effective intervention, though the studies were typically at high risk of bias. This highlighted the need for further high-quality large-scale studies in LMICs to assess the enablers and barriers, effectiveness, components, and mode of delivery of PR for CRDs.\n\nIn this feasibility study, the investigators will assess the resource infrastructure, optimal components of the PR programme, relevant CRDs eligibility, and model of service delivery for providing PR in Nigeria, South Africa and Cameroon, and then conduct a pilot randomised controlled trial (RCT). The investigators will also assess potential outcomes, including before and after intervention measurement of functional exercise capacity and relevant patient-reported outcomes. In qualitative interviews, the investigators will explore the barriers and enablers and stakeholders' opinions on implementing PR in each country.\n\nThe investigators will recruit (Nigeria - 30, South Africa - 30 and Cameroon - 30) clinically eligible patients and provide them with 8 weeks of either a centre- or community-based PR incorporating components derived from global PR guidelines and informed by the prior RESPIRE's systematic review and adapted to be deliverable in a low-resource setting. The investigators will assess the patients at baseline, end of the program (8 weeks) and then at 6 months follow-up to assess sustainability. Moreover, along with the quantitative assessment of outcomes (functional exercise capacity, health-related quality of life, dyspnoea severity and other secondary parameters), the investigators will conduct a qualitative interview with a purposive sample of patients, providers, and other health care professionals, e.g., GPs, pulmonologists, physiotherapists. The investigators will synthesise the findings for conference presentations, peer review publications, and advocate for PR with stakeholders.",[26],"Chronic Respiratory Conditions",[28,29,30,31,32,33,34,35,36],"COPD","Asthma","Tuberculosis","Chronic Respiratory Diseases","Africa","Nigeria","South Africa","Cameroon","Pulmonary Rehabilitation","NOT_YET_RECRUITING","2026-05-18",{"date":40,"type":41},"2026-05-22","ACTUAL",{"date":43,"type":20},"2026-09-01",{"date":45,"type":20},"2027-12-01",{"name":47,"class":48},"University of Edinburgh","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100595224","the-accredit-2-study-100595224","NCT07029672","The AcCREDiT 2 Study","Acute Respiratory Infections and Chronic Respiratory Disease Exacerbation Characterisation and Personalised Treatment Platform Study 2","ACCREDIT2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Clinically suspected acute respiratory infection or exacerbation of chronic respiratory disease\n* Availability of respiratory tract sample\n\n  1. Spontaneously breathing patients are able to produce a sputum sample\n  2. Mechanically ventilated patients in intensive care are due to have an Bronchoalveolar lavage or non-directed bronchial lavage for a clinical indication\n* Due to receive either:\n\n  1. an anti-infective agent (e.g. antibiotic, antiviral or antifungal) OR\n  2. a systemic anti-inflammatory agent (e.g. corticosteroid)\n* Valid informed consent, assent or enrolment through deferred consent\n* Re-enrolment will be allowed if presenting for a separate acute event\n\nExclusion Criteria:\n\n* Alternate respiratory cause of presentation in the opinion of the treating physician (e.g. pulmonary embolism, heart failure, etc.)\n* High clinical likelihood of infection with a Hazard Group 3 pathogen (e.g. tuberculosis, anthrax, plague)",{"count":58,"type":20},120,"OBSERVATIONAL","The ACCREDIT study - Acute respiratory infections and chronic respiratory disease exacerbations characterisation and personalised treatment platform study 2 (AcCREDiT 2).\n\nPatients with respiratory infections (such as pneumonia) or exacerbations of chronic respiratory conditions (such as emphysema) often require hospital admission. Infections or exacerbation are commonly caused by bacteria, viruses or fungi. In at least a quarter of patients no infectious cause of the exacerbation is found. Depending on the cause of the respiratory infections or exacerbations of chronic respiratory condition patients require prompt treatment with anti-infective drugs (antibiotics, anti-fungal or antiviral drugs) or anti-inflammatory drugs such as corticosteroids.\n\nPatients with respiratory infection or exacerbations of chronic respiratory conditions develop symptoms such as cough, sometimes with sputum, fever or breathlessness. These symptoms can be similar across several conditions, many of which are not due to infection (for example heart failure or blood clots in the lungs). When assessing patients with respiratory symptoms, clinicians face the challenge of limited information in the early stages of care as it takes three days to identify infectious organisms in the laboratory. Even when an infection is strongly suspected, distinguishing bacterial from viral or fungal infections on clinical grounds alone is difficult. This uncertainty often leads clinicians to prescribe a number of treatments, including antibiotics, before a clear diagnosis is made. Timely treatment is crucial for success and improved patient outcomes, especially for critically ill patients admitted to the intensive care unit (ICU). However, antibiotics may cause side effects, such as sickness and diarrhoea, and overuse of antibiotics leads to antibiotic resistance, making antibiotics less effective when they are really needed. Giving antibiotics to patients with an infection or exacerbation and avoiding antibiotics in patients without an infection requires rapid diagnostic tests. Furthermore, giving antibiotics prior to taking samples to diagnose infection can affect the sample being tested making it more likely to not give a useful result. For a diagnostic test for infection to be most useful it needs to be collected before an antibiotic is given - this is true for both clinical tests and those research tests which are clinical tests in development.\n\nModern technologies allow testing for an infection in hours rather than days. In order to understand how effective these technologies are, samples need to be taken from patients before they start treatment. In routine NHS care samples to test for infection should be taken before treatment has been started. However, in research studies samples are often taken up to a day after treatment has started which affects how effective the test is at finding infection. The forerunner to this study, called AcCREDiT, proposed investigating very rapid ways of identifying individuals with respiratory infection and exacerbation. However, the study team encountered challenges during the informed consent process, particularly with acutely unwell patients. Therefore, the AcCREDiT-2 was designed in collaboration with patients and public contributors to look at the feasibility of a modified informed consent process: verbal consent, assent for individuals with capacity to consent for themselves, and deferred consent.\n\nAcCREDiT-2 will be an observational study, meaning that no treatment will be changed, and no experimental drugs or tests used to influence the clinical care of participants. AcCREDiT-2 will also be a 'feasibility study', which is a smaller study designed to see what works well before embarking on a larger project. During the study the investigators will collect clinical information and samples, such as blood, sputum and stool, from patients who come to hospital with a presumed respiratory infection or exacerbation of their chronic respiratory condition. The investigators will compare new diagnostic tests to traditional laboratory tests to understand their relative advantages and disadvantages for patient care.\n\nThis is a 'feasibility' study, a small study ran first to make sure things work properly before expanding to a much larger study.",[26,28,62,63,64,65],"Pneumonia","Bacterial Infections","Viral Infections","Respiratory Exacerbation",[67],"ACCREDIT","2025-07-01",{"date":70,"type":41},"2025-07-04",{"date":68,"type":20},{"date":73,"type":20},"2026-04",{"name":75,"class":76},"Manchester University NHS Foundation Trust","OTHER_GOV",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":77},"100594116","assessing-the-burden-of-respiratory-syncytial-virus-rsv-100594116","NCT07015255","Assessing the Burden of Respiratory Syncytial Virus (RSV)","Assessing the Burden of Respiratory Syncytial Virus (RSV): the Assessment of the Burden of Respiratory Syncytial Virus (RSV) Across Different Age Groups and Risk Factors","Inclusion Criteria:\n\n* Patients of all ages with a confirmed diagnosis of RSV infection\n* Patients admitted to a SEHA hospital or healthcare facility between January 2018 and December 2024\n* Patients with documented data in the SEHA electronic medical record (EMR) system\n\nExclusion Criteria:\n\n* Patients with suspected RSV infection that is not laboratory-confirmed\n* Patients without sufficient data in the SEHA EMR system",{"count":86,"type":20},1500,"This study examines the impact of Respiratory Syncytial Virus (RSV) on people of all ages, from infants to the elderly. It uses hospital records collected between January 2018 and December 2024 to understand:\n\n* How often does RSV occur\n* Who is most at risk\n* The long-term and financial effects of RSV",[89,90,91,62,26],"Respiratory Syncytial Virus (RSV) Infection","Acute Lower Respiratory Tract Infections","Bronchiolitis",[93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,91,62,109,110,111],"Respiratory Syncytial Virus","RSV","RSV Infection","RSV in Infants","RSV in Adults","RSV Hospitalization","RSV Epidemiology","RSV Burden","RSV Risk Factors","Retrospective Study","Observational Study","ICU Admissions","RSV Mortality","RSV Cost Analysis","RSV Complications","Asthma and RSV","Recurrent Wheezing","RSV Surveillance","RSV-Related Comorbidities","2025-06-17",{"date":114,"type":41},"2025-06-19",{"date":116,"type":20},"2025-06",{"date":118,"type":20},"2026-06",{"name":120,"class":76},"Abu Dhabi Health Services Company"]